PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and ...
European Commission approves a higher 7.2 mg maintenance dose of Wegovy for obesity treatment across the EU. Dr Reddy's Laboratories prepares to launch a lower cost generic version of Wegovy in India.
NVO wins EU nod for a higher 7.2 mg Wegovy dose, unlocking stronger weight-loss results and a new step-up option for obesity care.
In AYAs, the ASH guideline panel recommends pediatric-inspired (asparaginase-containing) regimens for treatment-naïve B-ALL and T-ALL, and blinatumomab for relapsed/refractory B-ALL.
Q4 2025 Earnings Call February 19, 2026 4:30 PM ESTCompany ParticipantsCaitlin Lowie - Vice President of Corporate Communications ...
Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong ...
Rosemont Pharmaceuticals announces U.S. availability of ATMEKSI® (methocarbamol) Oral Suspension, a muscle relaxant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results